2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5803 High-dose chemotherapy and T-cell engager exposure is associated with CAR-T cell out-of-specification products in relapsed/refractory multiple myeloma

Jihong Song, MD, Youssef Samaha, MD2, Chiung-Yu Huang, PhD3, Adriana Rossi, MD4, Darren Pan, MD5, Zachary M. Avigan, MD, MHS6, Jodi Lipof, MD7, Cesar Rodriguez Valdes, MD8, Alfred Chung, MD9, Larysa Sanchez, MD10, Shambavi Richard, MD11, Samir Parekh, MD12, Shagun Arora, MD13, Jeffrey Lee Wolf, MD14, Joshua Richter I, MD15, Thomas Martin, MD16, Sundar Jagannath, M.D.17, Ajai Chari, MD18, Gurbakhash Kaur, MD,MA19, Anupama Deepa Kumar, MD20
1 University of California, San Francisco, San Francisco, California, United States
2 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
3 University of California, San Francisco, San Francisco, California, United States
4 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
5 University of California, San Francisco, San Francisco, California, United States
6 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
7 University of California, San Francisco, San Francisco, California, United States
8 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
9 University of California, San Francisco, San Francisco, California, United States
10 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
11 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
12 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
13 University of California, San Francisco, San Francisco, California, United States
14 University of California, San Francisco, San Francisco, California, United States
15 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
16 University of California, San Francisco, San Francisco, California, United States
17 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
18 University of California, San Francisco, San Francisco, California, United States
19 Icahn School of Medicine at Mount Sinai, New York, NY, California, United States
20 University of California, San Francisco, San Francisco, California, United States

Introduction: Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) is approved in early and late relapsed multiple myeloma (MM). Currently, there is limited data on risk factors that predict CAR T-cell therapy manufacturing failure (MF) or out-of-specification (OOS) products. Repeat or recent exposure to bendamustine is associated with manufacturing failure of CD19 CAR T-cell products in lymphoma. Emerging data suggest that exposure to bispecific antibodies (BsAb) in MM detrimentally impacts manufacturing outcomes. Here, using a multi-institutional, real-world database, we evaluate predictors of suboptimal manufacturing and compare clinical efficacy and safety outcomes between patients with successful and OOS CAR T-cell products.

Methods: We retrospectively reviewed 268 patients who underwent apheresis for ide-cel or cilta-cel at two institutions between 2021-2025 via the MoMMentum academic myeloma collaboration, after obtaining Institutional Review Board (IRB) approval. We captured patient-, disease-, and treatment-related characteristics, manufacturing outcomes, efficacy, and safety across 2 cohorts – patients who had successful CAR T-cell manufacturing and patients who had suboptimal manufacturing (OOS products or MF). We used univariate logistic regressions to evaluate predictors of OOS/MF. Multivariate and Cox models were fitted to evaluate progression free survival (PFS) and overall survival (OS).

Results: Forty-two patients had OOS products, 3 had failed manufacturing that required re-apheresis, and 223 had successful manufacturing (SM); this corresponded to a 17% OOS/MF rate. A higher proportion of patients in the OOS/MF group received cilta-cel than in the SM group (84% vs. 72%), although the difference did not reach statistical significance (p=0.10). Compared with the OOS/MF group, the SM group was older (median age 67 vs. 65 years; p = 0.14), had fewer prior lines of therapy (median 5 vs. 6; p<0.001), and had a similar absolute lymphocyte count at apheresis (0.8 vs. 0.9 x109/L; p=0.33). High-risk cytogenetic abnormalities were present in 67% of patients in both groups. Triple-class refractoriness was observed in 80% of the SM group and 96% of the OOS/MF group (p=0.09), while penta-drug refractoriness was present in 39% and 44%, respectively (p=0.61).

Median washout period from last therapy to apheresis was 29 days vs. 32 days (p=0.67) in the SM and OOS/MF groups. Length of washout period from last LOT and length of washout from last BsAb exposure was not significantly associated with manufacturing outcomes. Any prior exposure to VDPACE/VDCEP (p<0.001), BCNU (p=0.04), radiation therapy (p=0.03), and BsAb (p< 0.01) was associated with an increased risk of CAR-T manufacturing OOS/failure, whereas prior exposure to high-dose cyclophosphamide or melphalan was not significantly associated with manufacturing outcomes. Median PFS was 35 months in the SM group and 15 months in the OOS/MF group. Median OS was not reached in either group, and 2-yr OS was 85% in the SM  group and 69% in the OOS/MF group. When adjusting for LOT, high-risk status, triple-class refractoriness, and penta-drug refractoriness, there was no statistically significant difference in PFS (HR 1.22, 95% CI 0.78-1.92, p=0.4) or OS (HR 1.29, 95% CI: 0.68-2.43, p=0.4) between the SM and OOS/MF groups. Cytokine release syndrome (CRS) occurred in 89% of SM patients and 82% of OOS/MF patients, and ICANS occurred in 5% and 7%; there was no statistically significant difference in rate of occurrence and grade of these toxicities.

Conclusion: We demonstrate that exposure to BsAb, certain high-dose chemotherapy (VDPACE/VDCEP, BCNU), and radiation at any point prior to apheresis for CAR T-cell therapy were associated with an increased risk of OOS/MF. Washout period was not associated with manufacturing outcomes, perhaps due to institutional guidelines that ensure adequate duration of washout.  Strategies to improve manufacturing outcomes include collecting CAR T-cells in earlier LOT and saving high-dose chemotherapy, radiation, and BsAb for after apheresis, if clinically appropriate. We additionally demonstrate that OOS products obtained through expanded access programs are safe and effective in a real-world dataset. 

Jihong Song, MD: No relevant conflicts of interest to declare.